Paragonix Technologies Inc. Announces Filing Of A Second 510(k) Pre-Marketing Notification Application With The US Food And Drug Administration For The Paragonix Sherpa&#0153 Cardiac Transport System

Published: Nov 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRAINTREE, Mass.--(BUSINESS WIRE)--Paragonix Technologies, Inc. today announced that it has successfully completed filing of a second Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for its Paragonix Sherpa Pakā„¢ Cardiac Transport System1,2(CTS). The Sherpa Pak CTS is indicated for the static hypothermic preservation of hearts during transportation and eventual transplantation into a recipient, using cold storage solutions indicated for use with the heart. The current pre-market notification application intends to further identify user indications for the static hypothermic preservation of hearts during transportation.

Help employers find you! Check out all the jobs and post your resume.

Back to news